Tobacco and Vapes Bill (Second sitting)

Zubir Ahmed Excerpts

Committee stage
Tuesday 7th January 2025 Public Bill Committees

[Liz Jarvis (Eastleigh) (LD)]

Q Do you think the Bill goes far enough to protect children and young people from the harmful effects of tobacco and vaping?

Professor Linda Bauld: It is very ambitious on tobacco. We will be the first in the world—after unfortunate events in New Zealand, from my personal perspective—to introduce the smoke-free generation policy, and the world is looking at us. That is good. In terms of protecting people from vaping, the Bill has a proportionate set of measures, but if I come back to the answer that I gave to the shadow Minister, we really need to keep our eye on the regulations and—going back to the Minister’s questions—make sure that we are striking a balance. Given the evidence that we have for much stronger regulations on vaping, I think this strikes the right balance, but we need to make sure that we do that in a proportionate way. Finally, to go back to the comments from the previous set of witnesses, we also need to make sure that local areas have the flexibility around some of the measures to adapt them for their local circumstances.

[Dr Zubir Ahmed (Glasgow South West) (Lab)]

Q Thank you, Professor Bauld, for sharing your extensive expertise with us today. I want to explore the intersection between poverty and health, and where you think the Bill will have an impact. We know that health outcomes are poorer where there are pockets of high deprivation, as in many areas of Scotland, including my constituency of Glasgow South West. What are your thoughts, both quantifiable and general, as to the impact of this legislation on those children and on those particularly deprived communities?

Professor Linda Bauld: Dr Ahmed, you know—as Sir Gregor Smith said earlier—that smoking rates in our most deprived communities in Scotland are about 26%, compared with 6% in the least deprived. That is a very big number, and we see that pattern across the UK.

The Bill will make a difference in several respects. First, on preventing smoking uptake by gradually raising the age of sale, the evidence that we have from studies done by my colleagues at University College London and elsewhere is that previous rises in the age of sale have not exacerbated inequalities but have had a benefit in terms of preventing uptake. We know from the evidence that we have that those measures should be useful and helpful, and should not exacerbate that. The other thing is that, to go back to my earlier answer to the shadow Minister, by preventing smoking uptake in the groups that are likely to be future parents who are already likely to smoke, which are highly concentrated in our most deprived communities, we are going to have an impact there.

I do not see any signs in the Bill, when I look across the measures, that we will be exacerbating inequalities with it. I think that we will probably have the biggest impact in the areas where we have the most smokers which, unfortunately, are our most deprived communities.

--- Later in debate ---

[Sadik Al-Hassan]

Q I thought you said that there are no licensed products on the market?

Dr Laura Squire: There are not, which is why that is the way we would prefer to do it. Again, if we licensed these consumer products as a medicine, there are very strict requirements on labelling and on what needs to be given to the patient to explain what the product is and its risks. That is not there with these consumer cigarettes. It is going to get stricter under the new rules, but my preference would be that we give people more information.

[Dr Ahmed]

Q Thank you, Dr Squire, for being with us. The Royal College of Physicians has called for manufacturers to limit the production of toxic substances and for the MHRA to independently verify some of the contents of e-cigarettes. Do you think that that can be achieved through the measures in the Bill as it stands?

Dr Laura Squire: It depends on what happens with the actual regulations. At the moment, we do not have powers to test consumer e-cigarettes—that power sits with trading standards. Again, if we license something as a medicine, we go into absolute detail about what is in it. At the moment, it depends on what is in the regulations that come round. We do not do testing at the moment, and it would be important to think about the point at which any testing is done. If it is done at the point where something goes on to the register, that is fine and it tells you that the sample we saw at that point was compliant. But what happens later down the track? I think the role that trading standards has in doing that testing is really important, because it can do it post-market at any point. The question really is about the role of the MHRA—a medicines and healthcare products agency. Is it getting deeper into these consumer products where the risk is not outweighed by the benefits? That is an uncomfortable position for a medicines regulator.

--- Later in debate ---

[Liz Jarvis]

Q Lord Bichard mentioned Border Force. Will ensuring that it has enough resources to implement this Bill successfully be a consideration? In response to my question, Matthew Shanks mentioned a public health campaign. Are there any plans to have a public health campaign to back that up?

Andrew Gwynne: The short answer to both those questions is yes. We have committed to an investment across HMRC, trading standards and Border Force of £100 billion over the next five years to enforce these measures—sorry, it is £100 million. The Treasury will be having a fit; I am getting my billions and millions wrong. I wish it was £100 billion.

As far as public health campaigns are concerned, just this week we committed £70 million for smoking cessation. For this new year, I have signed off a concerted public health campaign for smoking cessation on social and broadcast media. As this Bill progresses and becomes law, there will be a huge public health publicity campaign so that everybody is aware of our Smokefree 2030 target ambitions.

[Dr Ahmed]

Q I have a couple of points, Minister. The first is to do with poverty and how the Bill will affect those who are disproportionately impacted not only by smoking but by second-hand smoke. We heard from our CMOs and Professor Bauld about the impact that smoking-related diseases have on those populations. It is not often in our lives that we get an opportunity to use an instrument that has the potential to change the trajectory of the lives of people who are at the lower end of the economic spectrum in society. What do you think will be the impact of the Bill on them?

Secondly, could you make a wider comment on the historical context of the Bill? In 2006, it was a Scottish Labour Government in the Scottish Parliament who set in train some of the processes that we are trying to finish today. Over those 14 to 15 years, we have seen many positive short-term and long-term public health outcomes. What do you think will be history’s judgment on this portion of that journey?